Lymphoma Clinical Trials in New York

Showing 221-240 of 344 trials

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

NCT03120676

This is a study with the purpose of studying the safety and efficacy of the study drug Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab could shrink cancer but it could also cause side effects. This study will also test any good and bad effects the study drug. Other aims include studying biomarkers that will help researchers understand how the drug works.

Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center3 participantsStarted Apr 2017

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Commack, New York, United States +3 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

NCT02518113

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma

Eli Lilly and Company36 participantsStarted Oct 2015

Duarte, California, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +19 more locations

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Lymphoma Trials in Other Cities

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Other Conditions in New York